Skip to Content
by Leigh MacMillan | Thursday, May. 8, 2014, 8:00 AM
Noninvasive biomarkers that detect programmed cell death – apoptosis – would be valuable for predicting early responses to anticancer therapies and for improving drug discovery. Potential targets for molecular imaging of apoptosis include caspase enzymes, which play essential roles in apoptotic signaling pathways.
H. Charles Manning, Ph.D., and colleagues used a caspase inhibitor as the basis for developing a PET (positron emission tomography) imaging probe to detect apoptosis in vivo. In the April 15 issue of Clinical Cancer Research, they report the development of a caspase inhibitor PET probe and demonstrate its utility in mouse models of human colorectal cancer. Using microPET imaging, they showed that the PET probe accumulated in tumors with elevated caspase activity – where tumor cells were dying following drug treatment.
The findings confirm the promise of the caspase inhibitor PET probe for detecting apoptosis in vivo. They suggest that this probe may be translatable to human imaging, where it could be used to assess early treatment responses and personalize cancer medicine.
These studies were supported by grants from the National Institutes of Health (CA140628, CA145138, CA127349, CA128323, CA095103, CA126588, RR017858, MH085768, DK058404, CA136440), with additional support from the Kleberg Foundation.
Send suggestions for articles to highlight in Aliquots and any other feedback about the column to firstname.lastname@example.org
Leigh MacMillan, (615) 322-4747
Health and Medicine, Reporter, Research Aliquots, cancer, cell death, Clinical Cancer Research, H. Charles Manning, Kleberg Foundation, NCATS, NCI, NIDDK, NIH, NIMH, personalized cancer medicine, PET imaging, positron emission tomography, radiology and radiological sciences, Reporter May 9 2014, tumor, Vanderbilt Ingram Cancer Center, Vanderbilt University Institute of Imaging Science
There are lots of ways to keep up with Vanderbilt. Choose your preferred method: